FY2025 EPS Estimates for YMAB Reduced by Cantor Fitzgerald

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. Cantor Fitzgerald analyst L. Watsek now expects that the company will earn ($0.92) per share for the year, down from their prior forecast of ($0.67). The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. During the same quarter last year, the firm earned ($0.02) EPS.

Several other research firms have also recently weighed in on YMAB. Truist Financial cut their price objective on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Bank of America lowered their price objective on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Morgan Stanley reduced their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $19.30.

Y-mAbs Therapeutics Trading Down 1.7 %

Shares of YMAB opened at $5.16 on Friday. Y-mAbs Therapeutics has a 1-year low of $4.25 and a 1-year high of $18.10. The firm’s 50-day moving average price is $6.34 and its 200-day moving average price is $10.54. The firm has a market capitalization of $231.11 million, a price-to-earnings ratio of -9.56 and a beta of 0.65.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of YMAB. State Street Corp increased its position in shares of Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares in the last quarter. Barclays PLC boosted its stake in Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after purchasing an additional 56,244 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Y-mAbs Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after purchasing an additional 47,846 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Y-mAbs Therapeutics in the third quarter worth $133,000. Finally, Caligan Partners LP lifted its holdings in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares in the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.